Company Overview - 博锐生物 has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and JPMorgan serving as joint sponsors [1] - The company is a leading integrated biopharmaceutical firm in China, focusing on comprehensive immunotherapy solutions for autoimmune and inflammatory diseases, as well as tumor immunology [1] - 博锐生物 ranks first among Chinese pharmaceutical companies in revenue from biologics for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [1] - The company has eight commercialized products and is transitioning from a proven molecule development enterprise to an innovation-driven biopharmaceutical company, including the development of ADC candidates [1] Industry Insights - The autoimmune disease market is one of the fastest-growing pharmaceutical sectors globally, with blockbuster drugs like Dupilumab, Risankizumab, and Ustekinumab each generating over $10 billion in revenue in 2024 [1] - In China, the market size for autoimmune diseases is projected to grow from RMB 17.4 billion in 2020 to RMB 32.8 billion in 2024, and is expected to reach RMB 289.9 billion by 2035, with a compound annual growth rate (CAGR) of 21.9% [1] - The market share of biologics is rapidly expanding, increasing from RMB 4.2 billion in 2020 to RMB 17.1 billion in 2024, and is anticipated to reach RMB 212.6 billion by 2035 [1] Tumor Immunology Market - Tumor immunology is a cornerstone of modern cancer treatment, utilizing the immune system to identify and eliminate cancer cells, encompassing cell immunotherapy, cytokines, cancer vaccines, and antibody therapies [2] - The success of immune checkpoint inhibitors has transformed the landscape of tumor treatment [2] - The proportion of tumor immunotherapy drugs in the overall oncology drug market in China is expected to grow from 11.3% in 2024 to 47.5% by 2035 [2] - The market size for tumor immunotherapy drugs in China is projected to increase from RMB 14.8 billion in 2020 to RMB 29.3 billion in 2024, and further expand to RMB 495.4 billion by 2035 [2]

Core Viewpoint - The announcement of potential tariffs on imported pharmaceuticals by the U.S. government is expected to impact the pharmaceutical industry, but many companies believe it will not significantly affect their performance in the near term [1][2]. Group 1: Tariff Impact and Company Responses - President Trump announced that the U.S. will initially impose "small tariffs" on imported drugs, potentially increasing to 250% over 18 months to boost domestic production [1]. - Companies like Pfizer and Amgen have indicated that they have sufficient production capacity in the U.S. to mitigate the impact of tariffs [2]. - Biogen expects that Trump's tariff policy will not significantly affect its profits this year, as a large portion of its revenue comes from domestic manufacturing [2]. - AbbVie stated that it will not be significantly impacted by tariffs due to its extensive U.S. manufacturing base and plans to continue investing in the U.S. [3]. Group 2: Manufacturing and Production Capabilities - Key indicators such as the number and geographical distribution of manufacturing plants, production facility utilization, and the origin of active pharmaceutical ingredients will determine a company's ability to withstand tariff risks [3][4]. - Companies like AbbVie, AstraZeneca, Eli Lilly, Merck, and Pfizer have the largest manufacturing networks in the U.S., each with over 10 major manufacturing plants [3]. - AbbVie, Eli Lilly, and BMS are among the few companies with more major plants in the U.S. than overseas, which positions them favorably against tariff impacts [4]. Group 3: Market Reactions and Financial Projections - The market reacted moderately to the tariff news, with Pfizer's stock rising over 5%, while others like Eli Lilly and Johnson & Johnson saw slight declines [1]. - Amgen raised its 2025 revenue forecast, reflecting the anticipated impact of tariffs, while not accounting for any future tax actions [2]. - Sanofi believes the impact of tariffs is manageable and has raised its sales growth forecast for the year [5].